Clinical Trial Update: A Clinical Trial on the Outcomes of Comprehensive Enhanced Prophylaxis Management (CEPM) in Chinese Patients With EGFR-Mutated Advanced NSCLC Receiving Amivantamab-Based Regimens [Phase 4]

View source ↗

Summary

This entry describes a Phase 4 clinical trial evaluating Comprehensive Enhanced Prophylaxis Management (CEPM) in Chinese patients with EGFR-mutated advanced non…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer
• Venous Thromboembolism

Drugs mentioned

• RYBREVANT (amivantamab-vmjw)

Snippet

Sponsor: Shanghai Pulmonary Hospital, Shanghai, China | Conditions: NSCLC (Advanced Non-small Cell Lung Cancer), VTE (Venous Thromboembolism) | Phase 4 | Status: NOT_YET_RECRUITING